Akston Initiates Clinical Study for Feline Weight Management Therapy at Cornell

Revolutionizing Feline Health: A Breakthrough in Weight Management
Pioneering a Novel Approach to Feline Weight Management
Akston has officially begun a clinical study at Cornell University's College of Veterinary Medicine. This trial is set to evaluate a groundbreaking once-weekly GLP-1 therapy specifically formulated for managing weight in cats. The study will involve domestic cats with overweight conditions, observed over a period of approximately three months.
The Escalating Challenge of Feline Obesity
Statistics from the Association for Pet Obesity Prevention reveal a concerning trend: in 2022, nearly two-thirds of American cats were categorized as overweight or obese. A more recent survey in 2024 indicated that 33% of cat owners identified their pets as having weight issues, an increase from 28% in the previous year, highlighting the growing scale of this health concern.
Unveiling Akston's Innovative GLP-1 Therapy
The core of Akston's therapeutic strategy is a GLP-1 protein, meticulously engineered to assist cats in regulating their appetite. Prior preclinical investigations conducted at Cornell University, utilizing laboratory cats, demonstrated the therapy's safety, reporting no observed adverse reactions or unexpected incidents. Pharmacokinetic analysis further confirmed the suitability of a once-weekly dosage regimen for the treatment.
The Science Behind Extended Efficacy
This groundbreaking therapy is developed leveraging Akston's proprietary Fc-fusion protein platform. This advanced technological base enables the precise design, synthesis, and rigorous testing of therapeutics. A key advantage of this platform is its capacity to fine-tune interactions with the immune system, thereby extending the duration of the therapy's action and enhancing its effectiveness.
Addressing a Critical Unmet Need in Veterinary Medicine
Dr. Todd Zion, co-founder and CEO of Akston, emphasized the significant impact of feline obesity, noting it as one of the most prevalent yet inadequately treated health problems in veterinary practice. He stated that by advancing this once-weekly GLP-1 therapy, Akston is directly confronting a substantial unmet need, aspiring to improve cats' health and extend their lifespans.
Enrollment Underway: A Collaborative Effort for Future Pet Health
The clinical study is currently enrolling participants at Cornell University. Initially, the goal is to enlist 70 cats, with potential plans to expand enrollment to 140. Dr. Patrick Carney, Associate Professor of Clinical Sciences at Cornell University College of Veterinary Medicine, expressed his enthusiasm for the potential of this tool. He highlighted that it could represent a significant breakthrough for veterinarians by providing a safe and effective solution where none currently exists.
Expanding Horizons: GLP-1 Therapy for Canine Companions
Akston is not solely focused on feline health; the company is also developing a GLP-1 program for dogs. This canine-focused initiative is progressing approximately six months behind the feline program, indicating a broader commitment to addressing pet obesity across different species.